Cancer treatment and research communications
Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study.
Yoshihito Kogure, Hiroya Hashimoto, Satoshi Ikeda, Toshiyuki Harada, Aoi Hino, Satoru Miura, Yasuhiro Goto, Keiichi Fujiwara, Nobuyuki Katakami, Kaoru Kubota, Naohiko Murata, Masahide Mori, Takashi Abe, Akiko M Saito, Nobuyuki Yamamoto
Published: 202610.1016/j.ctarc.2026.101094
Abstract
BACKGROUND: The CJLSG1901 phase 2 study evaluated efficacy and safety of pembrolizumab plus pemetrexed in older populations. A novel first-line approach for older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) was assessed.…
Preview only. Read the full abstract at the source